Get the Stockscreener App
26.98
0.33%
0.09
After Hours:
26.80
-0.18
-0.67%
Structure Therapeutics Inc Adr stock is traded at $26.98, with a volume of 542.05K.
It is up +0.33% in the last 24 hours and down -12.97% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$26.89
Open:
$27.27
24h Volume:
542.05K
Relative Volume:
0.66
Market Cap:
$1.51B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-12.15
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-0.22%
1M Performance:
-12.97%
6M Performance:
-39.59%
1Y Performance:
-39.82%
1-Day Range:
$26.06
$27.44
1-Week Range:
$23.50
$27.68
52-Week Range:
$23.50
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
26.98 | 1.51B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.83B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.81 | 39.72B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.48B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.01B | 3.30B | -501.07M | 1.03B | -2.1146 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
GAMMA Investing LLC Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Schrödinger Secures $150M Novartis Deal, Advances Three Clinical Programs for 2025 - StockTitan
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year LowShould You Sell? - MarketBeat
Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpHere's What Happened - MarketBeat
Stifel analysts initiate Structure Therapeutics stock with buy rating By Investing.com - Investing.com Canada
State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year LowShould You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% HigherStill a Buy? - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Time to Buy? - Defense World
Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6%Still a Buy? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC Wainwright - MarketBeat
Franklin Resources Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral obesity drug stock shows promise amid fierce competition - Investing.com
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year LowWhat's Next? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - Defense World
Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages - Defense World
Structure Therapeutics Advances Obesity Treatment Candidate - TipRanks
Structure Therapeutics Unveils Breakthrough Oral Obesity Drug, First-in-Class Amylin Agonist Shows Promise - StockTitan
Mcewen Mining Inc (MUX-N) QuotePress Release - The Globe and Mail
Structure Therapeutics' SWOT analysis: oral GLP-1 stock faces fierce competition - Investing.com
Market Factors: The biggest debatesand risksfor investors looking to outperform in 2025 - The Globe and Mail
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts - MarketBeat
Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail
2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart
Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Pier Capital LLC Buys 33,087 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Wellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Here’s Why - Defense World
FY2024 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Brokers Offer Predictions for GPCR FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bearish Outlook for GPCR FY2025 Earnings - Defense World
Bank of Montreal Can Has $1.94 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral GLP-1 stock shows promise amid fierce competition By Investing.com - Investing.com South Africa
84,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Readystate Asset Management LP - MarketBeat
Point72 Asset Management L.P. Purchases 820,589 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: oral GLP-1 stock shows promise amid fierce competition - Investing.com India
Structure CEO on the competitive landscape for oral GLP-1 drugs - CNBC
Janus Henderson Group PLC Buys 602,609 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Cinctive Capital Management LP Has $1.41 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 7.6% in November - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Structure Therapeutics Inc Adr Stock (GPCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 03 '24 |
Option Exercise |
0.34 |
106,200 |
36,108 |
191,907 |
0.05%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):